Developing differentiated medicines

for devastating diseases including inflammatory, fibrotic & immunological conditions, intractable cancers, lymphatic & GI diseases & neurological & neuropsychological disorders

Focus on the Brain Immune Gut (BIG) Axis

26 therapeutics and therapeutic candidates

15 are clinical stage

2 granted FDA clearance & European marketing authorization

Relationships with several pharma companies

or their investment arms

Team of world-class scientists and industry leaders


PureTech's Components of Value

 

Learn more about our unique discovery process

Wholly Owned Pipeline

Our programs*
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
LYT-100
Deupirfenidone
IPF & potentially other PF-ILDs
LYT-100
Deupirfenidone
Long COVID2 respiratory complications & related sequelae
LYT-100
Deupirfenidone
Lymphatic flow disorders, including lymphedema
LYT-200
Anti-Galectin-9 MAb
Solid tumors
LYT-210
Anti-Delta-1 MAb
Solid tumors
LYT-300
Oral Allopregnanolone
Neurological indications

Cash at Parent Level

Founded Entities

Publications
Internal Pipeline
PureTech's Lymphatic Leap
Gamma Delta T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation

CD4(+) T regulatory cells (T(regs)), which express the Foxp3 transcription factor, play a critical role in the maintenance of immune homeostasis. Here, we show that in mice, T(regs) were most abundant in the colonic mucosa.

Full Article

Vedanta
Science: The Gut’s Clostridium Cocktail
Press releases
2021-04-15
PureTech Announces Annual Results for Year Ended December 31, 2020
Press releases
2021-04-12
PureTech Presents Promising Preclinical Data from LYT-210 Immuno-Oncology Program at American Association for Cancer Research (AACR) Annual Meeting
Press releases
2021-04-07
PureTech to Present at Two Upcoming Investor Conferences

1 The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that our wholly-owned therapeutic candidates are safe or effective for use by the general public for any indication.

2 Long COVID is a term being used to describe the emerging and persistent complications following the resolution of COVID-19 infection, also known as post-acute COVID-19 syndrome (PACS).

3 Funding figure includes private equity financings, loans and promissory notes, public offerings or grant awards. Funding figure excludes future milestone considerations received in conjunction with partnerships and collaborations such as those with Boehringer Ingelheim, Imbrium Therapeutics L.P., Shionogi & Co., Ltd. or Eli Lilly. Funding figure does not include Vor’s gross proceeds of $203.4 million from its February 2021 post-period IPO or Karuna’s gross proceeds of $269.8 million from its February 2021 post-period follow-on offering. Calculated as of January 1, 2017 to December 31, 2020. 

4 This represents a non-IFRS number.  For a reconciliation of this number to IFRS, please see below:

 

 

 

 

 

Consolidated Cash Reserves is a non IFRS-measure which consists of cash, cash equivalents and short-term investments held at PureTech Health plc and consolidated subsidiaries. PureTech Level Cash Reserves is a non-IFRS measure which consists of cash, cash equivalents and short-term investments held at PureTech Health plc and only wholly-owned subsidiaries. PureTech Level Cash and Cash Equivalents is a non-IFRS measure which consists of cash and cash equivalents held at PureTech Health plc and only wholly-owned subsidiaries.